News

Thursday, 19. September 2019 | Filed under Company News

Company News: Novel Data on BellaSeno’s Biodegradable Breast Implants to Be Presented by Co-Founder DProf. Dietmar Hutmacher at Upcoming Plastic Surgery Conference

— Two presentations at the 50th Annual Conference of the German Society of Plastic, Reconstructive and Aesthetic Surgery (DGPRÄC)

— Recent publication in scientific journal Additive Manufacturing

BellaSeno GmbH, a company developing absorbable implants using additive manufacturing technologies, today announced that its co-founder Dietmar W. Hutmacher will introduce BellaSeno’s novel approach for breast reconstruction using 3-D-printed scaffolds during the 50th Annual Conference of the German Society of Plastic, Reconstructive and Aesthetic Surgery (DGPRÄC) in Hamburg, Germany.

Read more…

Wednesday, 18. September 2019 | Filed under Company News

Company News: Curetis Reports Financial Results for the First Six Months of 2019

Strategic transaction to combine businesses with OpGen Inc.

– Revenues increased by approximately 35% year-on-year

– Progressing regulatory product approvals in the U.S. and China

Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today reported its financial results for the first six months ended June 30, 2019, and provided a business update for 2019 year-to-date and its outlook for the future. Read more…

Monday, 16. September 2019 | Filed under Company News

Company News: Curetis Group Subsidiary Ares Genetics Signs R&D and Option Agreement with Leading Global IVD Corporation

— R&D collaboration to develop NGS-based predictive antibiotic resistance testing powered by ARESdb

— Partner to fund R&D and obtains option to license ARESdb and ARES Technology Platform for human clinical diagnostic use

Elements of this announcement contain or may contain inside information within the meaning of Article 7(1) of the Market Abuse Regulation.

Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that its wholly-owned subsidiary Ares Genetics GmbH (“Ares Genetics”), Vienna, Austria, has entered into a multi-phase partnership with an undisclosed leading global in vitro diagnostics corporation (the “Partner”) to jointly develop diagnostic solutions for infectious disease testing based on next-generation sequencing (“NGS”) technology. Read more…